Experimental safety switch reduces severity of CAR-T immunotherapy-related side effects
UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur. This advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia. It demonstrates a proof-of-principle for possible expanded use of CAR-T immunotherapy paired with the safety switch.
The researchers published their findings in the journal
Blood as an ahead-of-print publication.
With CAR-T therapy, T-cells from a patient s immune system are modified in a manufacturing facility to express part of an antibody that can bind to a surface protein on cancer cells. The modified T-cells, after being infused back into the patient, seek out and attack cancer cells throughout
E-Mail
IMAGE: Matthew Foster, MD, and his UNC Lineberger colleagues have used an experimental safety switch incorporated as part of a chimeric antigen receptor-modified T cell therapy (CAR-T) for an aggressive form. view more
Credit: UNC Lineberger Comprehensive Cancer Center
CHAPEL HILL, North Carolina UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur. This advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia. It demonstrates a proof-of-principle for possible expanded use of CAR-T immunotherapy paired with the safety switch.
Announcing the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: The study tested three conditions two were experimental and one was the control with messages on chemicals in cigarettes sent to participants for 15 consecutive days. The first message. view more
Credit: Goldstein, AO, et al., JAMA Network Open
CHAPEL HILL, N.C. For the last decade, the U.S. Food and Drug Administration has required tobacco manufacturers and importers to report the levels of harmful and potentially harmful chemicals found in their tobacco products and tobacco smoke. The idea was to educate the public and ultimately to decrease tobacco use, but little research has demonstrated if such information can impact on people s decisions to quit smoking.
UNC and Duke Rivals Unite to Fund New Metastatic Breast Cancer Research chapelboro.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chapelboro.com Daily Mail and Mail on Sunday newspapers.